SpringWorks Therapeutics
SWTX
SWTX was delisted on the 30th of June, 2025.
223 hedge funds and large institutions have $3.65B invested in SpringWorks Therapeutics in 2025 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 83 increasing their positions, 69 reducing their positions, and 132 closing their positions.
839% more call options, than puts
Call options by funds: $465M | Put options by funds: $49.6M
100% more funds holding in top 10
Funds holding in top 10: 9 → 18 (+9)
20% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 69
11% more capital invested
Capital invested by funds: $3.29B → $3.65B (+$357M)
3.59% more ownership
Funds ownership: 99.46% → 103.05% (+3.6%)
27% less funds holding
Funds holding: 306 → 223 (-83)
61% less first-time investments, than exits
New positions opened: 52 | Existing positions closed: 132
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCL
Glazer Capital LLC
New York
|
+$183M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
+$134M |
| 3 |
HI
HBK Investments
Dallas,
Texas
|
+$116M |
| 4 |
TAL
TIG Advisors LLC
New York
|
+$105M |
| 5 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
+$94.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$498M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$112M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$77.2M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$76M |
| 5 |
Pictet Asset Management
Carouge,
Switzerland
|
-$73.9M |
SWTX Hedge Fund Activity: Q2 2025 in Review
223 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q2 2025, worth a combined $3.65B — up 11% from $3.29B a quarter earlier.
Sellers outnumbered buyers: 132 funds closed out of SWTX and 52 opened new positions — a net loss of 80 holders — while 69 trimmed existing stakes and 83 added.
The largest buyer was Glazer Capital LLC, opening a new position worth an estimated $183M. The largest seller was Fidelity Investments, cutting an estimated $498M.
- 223 institutional investors held SpringWorks Therapeutics (SWTX) as of Q2 2025, down from 306 in Q1 2025.
- Funds reported $3.65B of SpringWorks Therapeutics stock for Q2 2025, up 11% quarter-over-quarter.
- 52 funds opened new SpringWorks Therapeutics positions in Q2 2025 and 132 closed out, a net change of -80 holders.
- The largest SpringWorks Therapeutics buyer in Q2 2025 was Glazer Capital LLC, an estimated $183M added.
- The largest SpringWorks Therapeutics seller in Q2 2025 was Fidelity Investments, an estimated $498M sold.
Based on aggregated 13F filings for Q2 2025.